Stock comparison
Bristol-Myers Squibb
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMY
Bristol-Myers Squibb
Market cap
$116.4B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMY | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 67B | IDXX |
| Benjamin Graham | 50C | 72B | IDXX |
| Philip Fisher | 39D | 67B | IDXX |
| Peter Lynch | 53C | 63C | IDXX |
| Joel Greenblatt | 27F | 75B | IDXX |
| Charlie Munger | 47D | 79B | IDXX |
| Terry Smith | 44D | 76B | IDXX |
Side-by-side metrics
| Metric | BMY | IDXX |
|---|---|---|
| Market cap | $116.4B | $42.11B |
| P/E (TTM) | 16.0x | 39.0x |
| EV/EBIT | 11.9x | 31.6x |
| ROIC (TTM) | 13.55% | 40.66% |
| Gross margin | 68.75% | 62.05% |
| Net margin | 15.01% | 24.63% |
| Revenue CAGR 5y | 0.96% | 7.56% |
| EPS CAGR 5y | 2.37% | 10.79% |
| Debt / Equity | 2.2x | 0.7x |
| Dividend yield | 4.39% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMY leads on
- Dividend yield4.39%vs 0.0%+100%
- Market cap$116.4Bvs $42.11B+64%
- EV/EBIT11.9xvs 31.6x+62%
- P/E (TTM)16.0xvs 39.0x+59%
IDXX leads on
- Revenue CAGR 5y7.56%vs 0.96%+87%
- EPS CAGR 5y10.79%vs 2.37%+78%
- Debt / Equity0.7xvs 2.2x+69%
- ROIC (TTM)40.66%vs 13.55%+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.